Though the efficacy of intravascular gene transfer has been demonstrated in native vessels following acute injury, this methodology has not been validated in complex models of vascular injury that more closely mimic clinical angioplasty procedures. Previous studies have shown that Gax gene overexpression modulates the injury-induced remodeling of the vessel in rat carotid and normal rabbit iliac arteries. Here, we evaluated the effect of the Gax gene delivery in atheromatous stented vessels. Rabbits were fed 120 g daily of 1% cholesterol diet for 3 weeks. At 1 week they underwent initial injury on the external iliac artery, then balloon angioplasty was performed at 3 weeks at the same site with a 2.5 mm diameter channel balloon catheter (three times 1 min at 6 atm). Either saline (n = 4) or the control viral construct Ad-CMVluc (5 × 10 9 p.f.u.) (n = 5) or Ad-CMVGax (5 × 10 9 p.f.u.) (n = 4) was delivered with a poloxamer mixture via a channel balloon (6 atm, 30 min), and a 15 mm long
Introduction
The excessive proliferation of vascular smooth muscle cells (VSMCs) in response to vessel wall injury contributes to the restenosis that occurs in 30-50% of patients undergoing balloon angioplasty 1 and is the main cause of restenosis following stent implantation. 2, 3 Endovascular stents represent one of the most significant advances in vascular interventional cardiology therapy, as two landmark clinical trials have established stents as the first mechanical intervention to have a favorable impact on the rate of restenosis. 4, 5 In both trials, stents proved superior to balloon angioplasty for primary lesions in large arteries with good distal flow. The success as achieved in these well-defined anatomic cohorts has prompted investigations designed to optimize stent biocompatibility further to broaden the application of this Palmaz-Schatz stent (PS154) was then deployed at the site (1 min, 8 atm). Arteries were analyzed 1 month later. At 1 month, the Ad-CMVGax treated arteries exhibited a lower maximal intimal area (1.15 ± 0.1 mm 2 ) than saline (1.87 ± 0.15 mm 2 , P = 0.007) or Ad-CMVluc-treated vessels (1.98 ± 0.31 mm 2 , P = 0.04). Likewise Ad-CMVGax-treated vessels displayed a lower maximal percentage cross-sectional area narrowing (35.1 ± 3.5%) than saline (65.3 ± 9.4%, P = 0.01) or Ad-CMVluc-treated vessels (62.7 ± 6.7%, P = 0.02). Angiographic analysis revealed larger minimal lumen diameter in Ad-CMVGax treated arteries (2.0 ± 0.1 mm) than saline (1.14 ± 0.36 mm, P = 0.06) or Ad-CMVluc-treated vessels (1.23 ± 0.25 mm, P = 0.02). Overexpression of the Gax gene inhibits neointimal hyperplasia and lumen loss in atheromatous stented rabbit iliac arteries. Gene Therapy (2000) 17, 1353-1361.
promising technology. However, restenosis within stents has proven to be a significant problem in the majority of procedures which do not conform to the Stress/ Benestent-defined lesion. 4, 5 Stent restenosis has been inferred to result from intimal proliferation, 3 and gene therapy has been proposed to reduce the frequency of this complication. 6 A number of growth factor-regulatable transcription factors have been identified in VSMCs that function to coordinate the expression of muscle-specific and cell cycle-regulatory genes in response to signaling pathways activated by vascular injury. 7, 8 Homeobox genes generally encode transcription factors that function to model the body plan and they control growth, differentiation, and migration at a cellular level. 9 The homeobox gene Gax (growth arrest homeobox) is expressed in adult cardiovascular tissues. 10, 11 Full-length Gax cDNA was initially isolated from adult rat aorta, 10, 12 but it is also expressed in developing cardiac muscle, skeletal muscle and neuronal tissues, 13 an expression pattern that may be regulated transcriptionally by MEF2/RSRF.
14 Tough Gax is expressed in quiescent adult smooth muscle cells, its expression is rapidly down-regulated when these cells are stimulated to proliferate with mitogens or when vessels are subjected to acute injury. 10, 15 Moreover, its expression is slowly up-regulated by conditions that result in growth arrest. 10, 16 This pattern of expression is reminiscent of the growth arrest-specific (gas) and growth arrest and DNA damage-inducible (gadd) genes that have been shown to encode a diverse group of proteins that can inhibit cell growth when overexpressed. [17] [18] [19] Gax is unique as a gas/gadd family member in that it is the only homeobox transcription factor to be identified with these expression characteristics. Other homeobox genes have been shown to function as regulators of cellular differentiation and growth, 7, 8 we have shown that overexpression of the Gax gene in normal rat carotid and rabbit iliac arteries can inhibit the fibro-proliferative response to balloon injury, 20, 21 an effect that may be mediated by its ability to suppress integrin expression. 22 Adenovirus-mediated gene transfer performed in atheromatous vessels [23] [24] [25] [26] [27] combined with stent implantation [28] [29] [30] [31] [32] [33] [34] constitute two important challenges for clinical application. Here, we present the results of percutaneous adenovirus-mediated Gax gene transfer to atheromatous, stented rabbit iliac arteries in a clinical model of balloon angioplasty performed with the channel balloon catheter. In this study, replication-defective adenovirus encoding the Gax gene was delivered percutaneously in a poloxamer mixture using a channel balloon angioplasty catheter without surgical exposure or side branch ligature of the target vessel. These data demonstrate that adenovirus-mediated Gax gene expression can inhibit the neointima formation and luminal narrowing in stented injured atheromatous vessels.
Results
Summary of in vivo gene transfer experiments A total of 22 cholesterol-fed rabbits underwent injury with latex balloon at the right external iliac artery. Two weeks later, these animals were subjected to balloon angioplasty, local delivery and stent placement at the site of the injury (Figure 1) . Two animals presented an occluded artery at the time of balloon angioplasty and were excluded of the following experiments. Five animals were used to assessed transfection efficiency with Ad-RSV␤gal (5 × 10 9 p.f.u.) at 3 days after virus delivery. Fifteen animals were randomized to evaluate minimal lumen diameter and intimal hyperplasia. Five of these animals were treated with saline (group 1), five animals were treated with 5 × 10 9 p.f.u. Ad-luc (group 2) and five animals were treated with 5 × 10 9 p.f.u. Ad-Gax (group 3). One saline and one Gax-treated animal died during the 4-week time course following local delivery, and were not available for final analysis. At the time of angioplasty there was an increase in plasma cholesterol levels in all groups, reaching 21.9 ± 9, 19.7 ± 11 and 19.7 ± 11 g/l in the saline, Ad-luc and Ad-Gax groups, respectively (P = NS).
Thrombotic occlusion
Thrombotic occlusion was a rare event in this series of experiment. No instance of thrombotic occlusion was observed in the stented vessels. Two acute thrombotic occlusions were observed following the first injury at the time of balloon angioplasty, local delivery and stent deployment before treatment randomization. These two animals were excluded before treatment allocation.
Quantitative analysis of histologic injury
The mean extent of vessel injury at the stent site (injury score) was 0.85 ± 0.04 for all the animals; 0.90 ± 0.06 in the saline group; 0.80 ± 0.08 in the Ad-CMVluc group and 0.88 ± 0.07 in the Ad-CMVGax group. Differences were not significant (P = NS).
Beta-galactosidase gene transfer
In the five rabbits transfected with Ad-RSV␤gal, gross examination revealed heterogeneous staining of the luminal surface of the artery, always confined to the area delimited by the length of the balloon (Figure 2A ). Microscopic examination at 3 days of 40 sections performed within the stented segment confirmed consistent endothelium denudation in all cases and demonstrated transfection of vascular smooth cells in the neointima layer of the arterial wall in all transfected vessels, with 12 ± 3.5 cells per section, the number of transfected cells ranging from 0 to 53 per section. Morphometric examination disclosed a low level of ␤-galactosidase transfection efficiency (1.1 ± 0.4%), consistent with previous reports. 24, 27 However, ␤-galactosidase-positive cells were localized to neointima cells near the site where stent struts are embedded in the vessel wall ( Figure 2B ). ␤-Galactosidase positive cells were identified as VSMCs by immunohistochemistry using a smooth muscle alpha actin antibody (not shown).
Arterial gene transfer of Ad-CMVGax increases minimal lumen diameter within stent Minimal lumen diameter 2 weeks after first injury, before balloon angioplasty and stent deployment, and treatment allocation was 1.11 ± 0.1 mm for the whole vessels and 1.19 ± 0.2 mm and 1.14 ± 0.1 mm and 1 ± 0.1 mm in the saline and Ad-CMVluc and Ad-CMVGax groups, respectively. No significant differences were observed among groups (P = NS). Angiographic minimal lumen diameter following stent implantation measured 2.14 ± 0.04 mm for all the animals and 2.14 ± 0.03 mm and 2.13 ± 0.08 mm and 2.15 ± 0.05 mm in the saline and AdCMVluc and Ad-CMVGax groups, respectively (P = NS).
Four weeks following local delivery and stent placement, Ad-CMVGax treated vessels exhibited a larger minimal lumen diameter, 2.0 ± 0.1 mm, than saline treated vessels, 1.14 ± 0.36 mm, P = 0.06, or Ad-CMVluctreated vessels, 1.23 ± 0.25 mm, P = 0.02 ( Figure 3) . Representative angiograms are shown in Figure 4 .
Arterial gene transfer of Ad-CMVGax attenuates intimal thickening within stent Four weeks after site-specific delivery, Ad-CMVGaxtreated vessels exhibited a lower maximal intimal area, 1.15 ± 0.01 mm 2 , than saline-treated vessels, 1.87 ± 0.15 mm 2 , P = 0.007, or Ad-CMVluc-treated vessels, 1.98 ± 0.31 mm 2 , P = 0.04, ( Figure 5 ). Maximal percentage crosssectional area narrowing was reduced to 35.1 ± 3.5% in the stented arteries treated by Ad-CMVGax and was significantly lower than saline-treated arteries 65.3 ± 9.4%, P = 0.01, or Ad-CMVluc-treated arteries, 62.7 ± 7.4%, P = 0.02 ( Figure 6 ). Representative photomicrographs of histologic cross-sections retrieved at necropsy from the stented arterial segments are shown in Figure 7 .
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Discussion
The results of the present experiments demonstrate that overexpression of the Gax gene in atheromatous stented vessels can increase minimal lumen diameter and reduce neointima formation within stent. More generally our results constitute the first report of percutaneous adenovirus-mediated gene delivery in atheromatousstented vessels.
VSMCs are an important target for arterial gene therapy for the prevention of restenosis after coronary angioplasty. 35, 36 Following the initial report of Lemarchand et al 37 several studies have clearly established recombinant defective adenoviral vectors as the most efficient vectors for arterial gene transfer. [38] [39] [40] [41] [42] [43] [44] In this setting, high transfection efficiencies 26, 38, [45] [46] [47] have been achieved in vivo in medial VSMCs using intraoperative gene delivery. However, even with these vectors, the efficiency of gene transfer to medial VSMCs using various percutaneous delivery systems remains limited; 23, 24, 35, 43, [48] [49] [50] this efficiency may be further decreased in some circumstances such as the presence of extensive atheromatous disease 24 while the use of higher adenoviral concentrations could be limited by acute tissue toxicity. 47 Since intraoperative delivery techniques are not relevant in humans to prevent restenosis after coronary angioplasty, percutaneous delivery would be required. Thus the ability to achieve transduction efficiency with percutaneous adenovirus-mediated gene transfer represents a critical step for cardiovascular gene therapy. We previously report that the use of poloxamer as a vehicle for adenoviral solution may constitute a significant advance towards the realization of this goal. 33 Then poloxamer was systematically used in our experiments in atheromatous stented vessels.
Recent developments in interventional cardiology, with the increasing use of endovascular stents, make arterial gene transfer in conjunction with stent implantation an area of particular interest. Coronary stents constitute, indeed, one of the most significant advances in vascular interventional therapy. A recent reduction in the initially high rate of periprocedural complications 51, 52 and the demonstration of their efficacy in decreasing restenosis 4,5 has led to a marked increase in the use of stenting in clinical practice. However the restenosis rate, although less, is still in the 15-25% range. Studies designed to determine the basis for stent restenosis have suggested that this is most frequently due to intimal hyperplasia 2, 3 especially in small vessels. 2 Thus strategies with demonstrated inhibitory effect on smooth muscle proliferation and intimal hyperplasia could have a beneficial impact on in-stent restenosis. Certain of these strategies, involving genes encoding for cell cycle regulatory proteins, 21 ,46,53 molecules that are secreted, 54 
enzymes with
Gene Therapy products acting locally (eg herpes simplex virus 1 thymidine kinase, NO synthase, cytosine deaminase), 26, 27, [55] [56] [57] [58] [59] have been developed with adenoviral vectors designed to optimize transfection efficiency. A previous report has demonstrated that gene transfer to the neointima 1 month after stent implantation was feasible. 23 However, there is to date no published data on the feasibility of gene transfer in conjunction with stent implantation in atheromatous stented vessels. The potential use of gene therapy as a strategy designed to optimize the biocompatibility of endovascular stents must also be considered within the context of alternative strategies, using either coated or eluting stents, 31 some of which are currently in early clinical trials. 60 We have to point out, however, that these strategies require modified stents while in the present series of experiments commercially available metallic stents were used.
In this study a replication defective adenovirus encoding Gax was delivered percutaneously in atheromatous stented vessels using a channel balloon catheter. Fifteen animals were randomly assigned to receive either saline or Ad-CMVluc or Ad-CMVGax. Analyses of cross-sections of the iliac arteries harvested at 28 days after angioplasty and stent implantation revealed a significant 54% reduction in the neointima formation and a corresponding increase in lumen diameter of the Ad-CMVGaxtreated arteries relative to the control-treated arteries and is similar to a previous report. 21 The inhibitory action of Ad-CMVGax is likely to derive, at least in part, from its ability to inhibit cellular proliferation, via its ability to up-regulate the cyclin-dependent kinase inhibitor p21. 20 However, homeodomain transcription factors are widely recognized to function as pleiotropic regulators and gax overexpression may also affect VSMC differentiation, migration or viability. 22, 61, 62 In contrast to the Ad-Gaxtreated arteries, no discernible difference was seen in the extent of neointima formation between the Ad-CMVluctreated and saline-treated arteries in the control group of animals. The ability of Gax overexpression to inhibit neointima formation compares favorably with previous recent results reported by other groups using adenovirusencoded genes for wild-type and mutant form of RB in rat and porcine models, 46 ,63 the herpes simplex virus thymidine kinase gene in rat, rabbit and porcine models, 26, 27, 55, 56 p21 53 in the rat model and hirudin in the rat model. 54 Overall, the reduction in intima/media ratio achieved with these agents ranged from 35 to 50%.
The rate of gene transfer in this study was low. It is however consistent with previously published results in similar models using similar methods of gene delivery without stent implantation. 24, 27 Thus, a number of possible explanations can account for the apparent discrepancy between the magnitude of the Ad-Gax biologic effect with a larger minimal lumen diameter and a significant reduction in neointima formation and the transduction efficiency estimated from ␤-galactosidase activity. First, the rate of transfection using the nuclear targeted ␤-galactosidase reporter gene may be misleading because X-gal staining is a relatively insensitive method for assessment of transfer efficiency 64 and it substantially underestimates the true transfection frequency. In support of this hypothesis, it has been reported that adenovirus-infected culture of VSMCs harbor latent ␤-galactosidase activity that can be detected only when cells are exposed to agents that boots transgene expression from the CMV promoter. 65 This issue may be particularly relevant to the current study since ␤-galactosidase was expressed from the RSV LTR, a weaker transcriptional regulator in VSMCs than the CMV promoter. Alternatively, the VSMCs that are most likely to migrate and proliferate, ie those at the sites of greatest injury at the stent struts, may be preferentially exposed to infection by virus as we observed.
Gene transfer combined with endovascular stent implantation in atheromatous vessels constitute two important challenges for percutaneous adenovirusmediated gene transfer to the vessel wall. This study demonstrates that overexpression of Gax gene in atheromatous stented vessels can increase minimal lumen diameter and reduce neointima formation. These results suggest therapeutic strategy for the treatment of restenosis in stented vessels.
Materials and methods

Recombinant adenoviral vectors
Replication-defective recombinant adenoviral vectors, based on human adenovirus 5 serotype, were produced as previously described. [66] [67] [68] Ad-CMVGax included the rat gax gene cDNA under the cytomegalovirus early promoter and has already been described. 21 Ad-RSV␤gal contains the Escherichia coli lacZ gene and the SV40 early region nuclear localization sequence (nls). nlslacZ gene encodes a nuclear-targeted ␤-galactosidase under the control of the Rous sarcoma virus promoter. 67 Another E1-deleted recombinant adenovirus referred to as AdCMVluc was used in this study (a gift from Dr JJ Robert, CNRS-UMR 9923, Paris). Ad-CMVluc encodes the firefly luciferase gene driven by the enhancer/promoter of the immediate-early gene of human cytomegalovirus. The CMVluc cassette inserted in the adenoviral vector construct was derived from the expression vector pUT 650 (CAYLA, Avenue de Larrieu, Toulouse, France). Viral titer was determined by plaque assay on 293 cells as previously described 69 and expressed as 5 p.f.u. per ml. Viral stocks were stored at −80°C and thawed on ice 15 min before use. To prevent variations in the transfer efficiency related to variations between stocks, only one viral stock was used for all the experiments performed with each adenoviral vector.
Either saline (50 l) or recombinant adenoviruses (5 × 10 9 p.f.u. in 50 l of storage buffer) were diluted immediately before use in 150 l of a 20% solution of poloxamer 407 (BASF) as previously described. 33 Previous study in two different species have demonstrated the increase by two-to three-fold of the transfection efficiency using the poloxamer 407 in normal and stented vessels. 33, 70, 71 Then poloxamer was systematically used in these series of experiments.
Animal model (Figure 1 ) Animal protocols were approved by St Elizabeth's Medical Center Institutional Animal Care and Use Committee. All animals received aspirin 50 mg daily for 7 days before the initial intervention and until death. Before each procedure, heparin sodium (1000 USP units, Elkins-sinn, Cherry Hill, NJ, USA) was administered intra-arterially to prevent acute occlusion of the balloon-injured sites. Male NZW rabbits, weighing approximately 4 kg (Pine Acre Rabbitry, Norton, MA, USA), were fed 120 g daily of a 1% cholesterol diet. One week after starting the diet, they were anesthetized with ketamine (10 mg/kg) and acepromazine (0.2 mg/kg) following premedication with xylazine (2 mg/kg). After left carotid artery cutdown, a 4 French latex balloon catheter (Baxter, Deerfield, IL, USA) was advanced into the femoral artery under fluoroscopy. Endothelial abrasion of the right external iliac arteries was achieved by three passages of the inflated balloon.
Angioplasty, gene delivery and stent implantation Two weeks after arterial injury, the animals were anesthetized in a similar fashion and a 5 Fr introducer sheath (Terumo, Tokyo, Japan) was positioned in the femoral artery under surgical exposure, following which nitroglycerin (0.20 mg, SoloPak, Franklin Park, IL, USA) was administered intra-arterially. All catheters were subsequently introduced through this sheath. A 2.5 × 20 mm channel balloon catheter (Boston Scientific, Watertown, MA, USA) was advanced over a 0.014-in guide wire (HiTorque Floppy II; Advanced Cardiovascular Systems, Temecula, CA, USA) into the right external iliac artery after reference angiogram. Balloon inflation was then performed three times for 1 min each at 6 atm with a rest of 1 min between each inflation. The catheter was then inflated at 6 atm and either 200 l of the mixture of the poloxamer and viral solution or 200 l or the mixture of the poloxamer and saline was instilled through the infusion port of the catheter. The solution was instilled slowly (120 s) through the infusion port of the catheter at low pressure (100-150 mm Hg). After 30-min incubation, the balloon was deflated and the catheter was removed. Stent implantation was performed using a 15-mm long Palmaz-Schatz coronary stent (PS 154) (Johnson and Johnson Interventional Systems, Warren, NJ, USA) over a 2.5 × 20 mm angioplasty balloon catheter (Boston Scientific) and opposed to the vessel wall at 8 atm. The cholesterol diet was replaced with a normal rabbit chow.
Evaluation of gene transfer
The site of gene expression was studied in five animals transfected with an adenovirus encoding for nuclear targeted ␤-galactosidase (Ad-RSV␤gal 5 × 10 9 p.f.u. in 50 l of storage buffer were diluted immediately before use in 150 l of a 20% solution of poloxamer 407 (BASF)) and the animals were killed at day 3 by pentobarbital overdose. Target stented segments were cautiously retrieved, washed in saline, and cut longitudinally. The stent was taken out before staining. To assess nlslacZ gene expression, the arteries were harvested and stained with the substrate 5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside (X-gal, Sigma Chemical, St Louis, MO, USA) as reagent for 2 h, at 37°C, as previously described. 24, 49 After staining, transfected iliac arteries were rinsed in saline, photographed through a dissecting microscope and four serial 5-mm long segments were taken from the target zone. Arterial segments were then mounted, cut into 5-m sections, and counter-stained with hematoxylin and eosin or Richardson's elastic trichrome. Expression of the nlslacZ gene was considered positive only when dark blue staining of the nucleus was observed. To determine which cell types within the arterial wall expressed the transgene, immunohistochemical staining of X-galstained arterial sections was performed using, as a pri-mary antibody, a mouse monoclonal antibody specific for smooth muscle alpha-actin (Sigma). Briefly, this involved preincubation in blocking serum and application of the primary alpha-actin alkaline phosphatase conjugated mouse antibody at a dilution of 1:300, overnight at 4°C. After three washes in straight PBS, bound antibody was detected by incubating the sections in fast red complex (Biogenex, San Ramon, CA, USA) to give a red-pink reaction product.
Transgene expression 3 days after delivery was quantified using morphometric analysis in five animals after X-gal staining. For each transfected iliac artery, four serial 5-mm long segments were taken from the target zone. From each 5-mm segment, two random 5-m thick sections were examined by light microscopy by two operators blinded to treatment. For each artery, eight different levels were available for quantification through the entire length of the target zone and a total of 40 sections were examined for each animal. Transfection efficiency was determined by counting stained versus total medial nuclei in each arterial section.
Quantitative angiography
Four weeks after angioplasty, gene delivery and stent implantation, the animals were anesthetized in a similar fashion and a 5 Fr introducer sheath was positioned in the right carotid artery. A final angiogram was performed via a 3 Fr, end-hole infusion catheter (Tracker-18; Target Therapeutics, San Jose, CA, USA) following nitroglycerin injection.
Angiograms of the external iliac arteries after stent implantation and at the date of death were obtained for each animal. Quantitative analysis was performed using a computerized analysis system (Image Comm, Santa Clara, CA, USA) that has previously been validated. 72 
Evaluation of intimal hyperplasia
Following in vivo measurements, a complementary bolus of heparin (2000 IU) was administered via the ear vein. A cannula was inserted into the lower abdominal aorta to perfuse in situ a total of 500 ml of 5% dextrose solution with 100 units/ml heparin. Animals were killed by pentobarbital overdose and then arteries were pressureperfused at 100 mm Hg for 2 h with 10% buffered formalin.
Stents were embedded in methyl methacrylate plastic (Sigma) as previously described. 34 Plastic sections were cut with a low speed diamond wafer mounted on the Buelher Isomet saw (Buelher, Evanston, IL, USA). Fiftym sections were cut and stained on one side with metachromatic stain. The sections were air dried and mounted in oil immersion liquid. Surface area were quantified with a Nikon Labophot compound microscope equipped with 2 × to 10 × objectives and a pair of 10 × eye pieces (Nikon, Melville, NY, USA). The visual field of the microscope was integrated to the LED-lit cursor of a standard digitizing pad through a drawing tube attachment with a 1.25 × magnification factor. Measurements were carried out using Sigmascan morphometric software (Jandel Scientific, San Rafael, CA, USA) on an Intel/486-based personal computer system. Integration of the microscope with the computer via the digitizing tablet facilitated direct examination of the surface at magnifications ranging from 25 × to 125 ×. Eight sections, systematically retrieved from the length of the specimen, were measGene Therapy ured. For each section, the areas of the neointima, media, total vessel, and native lumen (delineated by the internal elastic lamina) were determined. Percent luminal obstruction was calculated for each section as (intimal area/native lumen area) × 100. Injury score was evaluated for each section. 73 Thrombotic occlusion precluded the quantitative analyses described above. Accordingly, such specimens were not included in these analyses.
Statistical analysis
All results are expressed as mean ± standard error (± s.e.). Statistical significance was evaluated using a non-parametric U Mann-Witney test for comparisons between two means. A value of P Ͻ 0.05 was interpreted to denote statistical significance.
